FI3882249T3 - Ruksolitinibin deuteroidut johdannaiset - Google Patents

Ruksolitinibin deuteroidut johdannaiset

Info

Publication number
FI3882249T3
FI3882249T3 FIEP21156398.6T FI21156398T FI3882249T3 FI 3882249 T3 FI3882249 T3 FI 3882249T3 FI 21156398 T FI21156398 T FI 21156398T FI 3882249 T3 FI3882249 T3 FI 3882249T3
Authority
FI
Finland
Prior art keywords
pharmaceutically acceptable
acceptable salt
myelofibrosis
deuterium
letter
Prior art date
Application number
FIEP21156398.6T
Other languages
English (en)
Finnish (fi)
Inventor
I Robert Silverman
Julie F Liu
Adam J Morgan
Bhaumik Pandya
Scott L Harbeson
Original Assignee
Sun Pharmaceutical Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3882249(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Inc filed Critical Sun Pharmaceutical Ind Inc
Application granted granted Critical
Publication of FI3882249T3 publication Critical patent/FI3882249T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FIEP21156398.6T 2012-06-15 2013-06-14 Ruksolitinibin deuteroidut johdannaiset FI3882249T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261660428P 2012-06-15 2012-06-15
US201261678795P 2012-08-02 2012-08-02

Publications (1)

Publication Number Publication Date
FI3882249T3 true FI3882249T3 (fi) 2025-08-11

Family

ID=48699982

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21156398.6T FI3882249T3 (fi) 2012-06-15 2013-06-14 Ruksolitinibin deuteroidut johdannaiset

Country Status (19)

Country Link
US (7) US20150197525A1 (cg-RX-API-DMAC10.html)
EP (4) EP3450434B1 (cg-RX-API-DMAC10.html)
AU (3) AU2013274030B2 (cg-RX-API-DMAC10.html)
BR (1) BR122023027277A2 (cg-RX-API-DMAC10.html)
CA (1) CA2876306C (cg-RX-API-DMAC10.html)
DK (2) DK3882249T3 (cg-RX-API-DMAC10.html)
EA (1) EA201492287A1 (cg-RX-API-DMAC10.html)
ES (2) ES2867048T3 (cg-RX-API-DMAC10.html)
FI (1) FI3882249T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20250965T1 (cg-RX-API-DMAC10.html)
IN (1) IN2014DN10670A (cg-RX-API-DMAC10.html)
LT (1) LT3882249T (cg-RX-API-DMAC10.html)
MX (2) MX360495B (cg-RX-API-DMAC10.html)
PL (2) PL3882249T3 (cg-RX-API-DMAC10.html)
PT (1) PT3882249T (cg-RX-API-DMAC10.html)
RS (1) RS67061B1 (cg-RX-API-DMAC10.html)
SI (1) SI3882249T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202500302T1 (cg-RX-API-DMAC10.html)
WO (1) WO2013188783A1 (cg-RX-API-DMAC10.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3184526T1 (sl) 2005-12-13 2019-03-29 Incyte Holdings Corporation Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
EP2721028B1 (en) 2011-06-20 2015-11-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
BR122023027277A2 (pt) 2012-06-15 2024-01-23 Concert Pharmaceuticals, Inc. Derivados deuterados de ruxolitinib e composição farmacêutica
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
LT3030227T (lt) 2013-08-07 2020-06-10 Incyte Corporation Prailginto atpalaidavimo jak1 inhibitoriaus dozavimo formos
EP3148545B1 (en) 2014-05-28 2023-03-15 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
EP3325479B1 (en) 2015-06-03 2020-12-02 UWM Research Foundation, Inc. Ligands selective to alpha 6 subunit-containing gabaa receptors and their methods of use
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
CN108697700B (zh) 2016-02-04 2021-08-17 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
AU2017217806A1 (en) * 2016-02-12 2018-08-16 Vertex Pharmaceuticals (Europe) Limited Deuterium-modified CFTR modulators
AU2017261286B2 (en) * 2016-05-04 2023-03-23 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
CA3045666A1 (en) * 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
WO2019104225A1 (en) 2017-11-22 2019-05-31 Dauntless 2, Inc. Therapeutic compound formulations
US20200353419A1 (en) 2017-11-22 2020-11-12 Dauntless 1, Inc. Membrane emulsification device for microsphere creation
US11179412B2 (en) * 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EP3762424A1 (en) 2018-03-08 2021-01-13 Novartis AG Use of an anti-p-selectin antibody
SI3773593T1 (sl) 2018-03-30 2024-08-30 Incyte Corporation Zdravljenje hidradenitisa suppurative z zaviralci jak
MA52655A (fr) 2018-03-30 2021-02-17 Incyte Corp Biomarqueurs pour maladie cutanée inflammatoire
MA52208A (fr) 2018-04-13 2021-02-17 Incyte Corp Biomarqueurs pour une maladie du greffon contre l'hôte
WO2020039401A1 (en) 2018-08-24 2020-02-27 Novartis Ag Treatment comprising il-1βeta binding antibodies and combinations thereof
WO2020163653A1 (en) * 2019-02-06 2020-08-13 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
PH12021552130A1 (en) 2019-03-05 2022-08-31 Incyte Corp Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
WO2020210125A1 (en) 2019-04-10 2020-10-15 University Of Notre Dame Du Lac Deuterated antimicrobial compounds
WO2020223640A1 (en) 2019-05-02 2020-11-05 Intel Corporation Quality of service (qos) in information centric networking (icn)
WO2020236950A1 (en) 2019-05-21 2020-11-26 Dauntless 1, Inc. Therapeutic microsphere formulations containing charged polymers
US20220331318A1 (en) 2019-09-16 2022-10-20 Novartis Ag Use of an mdm2 inhibitor for the treatment of myelofibrosis
JP2022548627A (ja) 2019-09-16 2022-11-21 ノバルティス アーゲー 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用
WO2021062163A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
US12203942B2 (en) 2019-10-10 2025-01-21 Incyte Corporation Biomarkers for graft-versus-host disease
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
AU2020388638A1 (en) 2019-11-22 2022-06-30 Incyte Corporation Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022036030A1 (en) 2020-08-12 2022-02-17 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
US20240000777A1 (en) 2020-10-08 2024-01-04 Novartis Ag Use of an erk inhibitor for the treatment of myelofibrosis
WO2022094133A1 (en) 2020-10-28 2022-05-05 Concert Pharmaceuticals, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
WO2022107131A1 (en) * 2020-11-19 2022-05-27 Sol-Gel Technologies Ltd. Ruxolitinib or deuterated ruxolitinib composition and uses thereof
US12005067B2 (en) 2020-12-04 2024-06-11 Incyte Corporation JAK inhibitor with a vitamin D analog for treatment of skin diseases
WO2022150676A1 (en) 2021-01-11 2022-07-14 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor
CN114853760B (zh) * 2021-02-03 2025-12-05 南京正大天晴制药有限公司 一种芦可替尼中间体的制备方法
JP2024531188A (ja) * 2021-08-11 2024-08-29 サン ファーマシューティカル インダストリーズ，インコーポレイテッド 重水素化ｊａｋ阻害剤による脱毛障害の治療
CA3228509A1 (en) 2021-08-12 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CN113820413B (zh) * 2021-09-17 2023-04-07 重庆华邦胜凯制药有限公司 高效液相色谱法分离测定磷酸芦可替尼及杂质的方法
JP2025515051A (ja) 2022-05-04 2025-05-13 サン ファーマシューティカル インダストリーズ，インコーポレイテッド 重水素化ｊａｋ阻害剤による治療のための投与レジメン
CN117384163A (zh) * 2022-07-05 2024-01-12 盛世泰科生物医药技术(苏州)股份有限公司 一种含偕二氟基的化合物及其制备方法和用途
EP4680231A1 (en) * 2023-03-17 2026-01-21 Mayo Foundation for Medical Education and Research Use of oral jak kinase inhibitors to treat lichen planus
CN120917022A (zh) 2023-03-23 2025-11-07 葛兰素史密斯克莱知识产权(第3号)有限公司 氘代p2x3调节剂
US12364699B2 (en) 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
WO2025226637A1 (en) 2024-04-22 2025-10-30 Incyte Corporation Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
EP1390063B1 (en) 2001-05-03 2004-11-17 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
SI3184526T1 (sl) * 2005-12-13 2019-03-29 Incyte Holdings Corporation Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010502702A (ja) * 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
MX2009013402A (es) * 2007-06-13 2010-02-24 Incyte Corp Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP2242493B1 (en) 2008-01-22 2013-06-05 Concert Pharmaceuticals Inc. Derivatives of gefitinib
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
BR122023027277A2 (pt) 2012-06-15 2024-01-23 Concert Pharmaceuticals, Inc. Derivados deuterados de ruxolitinib e composição farmacêutica
PL2919766T3 (pl) * 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu

Also Published As

Publication number Publication date
US20190308976A1 (en) 2019-10-10
EP3882249A1 (en) 2021-09-22
SI3882249T1 (sl) 2025-10-30
CA2876306A1 (en) 2013-12-19
PT3882249T (pt) 2025-08-06
SMT202500302T1 (it) 2025-09-12
IN2014DN10670A (cg-RX-API-DMAC10.html) 2015-08-28
US20170239254A1 (en) 2017-08-24
EP3450434B1 (en) 2021-02-24
HRP20250965T1 (hr) 2025-10-10
EP3882249B1 (en) 2025-05-14
RS67061B1 (sr) 2025-08-29
MX2014015185A (es) 2015-02-17
EP2861600A1 (en) 2015-04-22
US20210330674A1 (en) 2021-10-28
AU2016238877A1 (en) 2016-10-27
WO2013188783A8 (en) 2014-02-27
AU2013274030A1 (en) 2015-01-22
MX373123B (es) 2020-04-27
US20250025467A1 (en) 2025-01-23
DK3450434T3 (da) 2021-05-03
PL3450434T3 (pl) 2021-10-04
BR112014031204A2 (pt) 2017-06-27
EP4606434A2 (en) 2025-08-27
EA201492287A1 (ru) 2015-07-30
MX360495B (es) 2018-11-06
EP4606434A3 (en) 2025-12-03
US9249149B2 (en) 2016-02-02
ES3037872T3 (en) 2025-10-07
LT3882249T (lt) 2025-08-25
PL3882249T3 (pl) 2025-09-08
EP3450434A1 (en) 2019-03-06
US20150197525A1 (en) 2015-07-16
US20150239896A1 (en) 2015-08-27
US20230355629A1 (en) 2023-11-09
DK3882249T3 (da) 2025-08-25
AU2018271227A1 (en) 2018-12-13
ES2867048T3 (es) 2021-10-20
AU2013274030B2 (en) 2016-07-07
WO2013188783A1 (en) 2013-12-19
AU2016238877B2 (en) 2018-08-30
BR122023027277A2 (pt) 2024-01-23
AU2018271227B2 (en) 2020-08-27
CA2876306C (en) 2024-02-20

Similar Documents

Publication Publication Date Title
FI3882249T3 (fi) Ruksolitinibin deuteroidut johdannaiset
ECSP19043254A (es) Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2
PH12017501419A1 (en) Therapeutically active compounds and their method of use
CL2021000178A1 (es) Compuestos de piridin-2-ona útiles como antagonistas de smarca2
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
BR112015025901A8 (pt) composto, composição, kit, e, uso de um composto
BR112014009365A2 (pt) método para inibição da atividade de deubiquitinação
PH12013501427B1 (en) Melanin modification compositions and methods of use
MX2016007777A (es) Modelado de fibras de queratina con el uso de acido oxoetanoico y/o derivados de este.
MY183661A (en) Treatment of cancer with tor kinase inhibitors
MD20160016A2 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
BR112014029708A2 (pt) composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina
PH12021552395A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
MX2016008157A (es) Modelado de fibras de queratina con el uso de un agente activo que comprende al menos dos grupos funcionales seleccionados de: -c(oh)- y -c(=o)oh.
JP2015117185A5 (cg-RX-API-DMAC10.html)
JP2015500884A5 (cg-RX-API-DMAC10.html)
PE20091714A1 (es) Combinacion del inhibidor hgf y el agonista pten
ECSP22011746A (es) Agentes antipalúdicos
NZ705389A (en) Methods of treating hair related conditions
ZA202403327B (en) Halogenated phenylarsine oxide compound and application thereof
PH12021552110A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
EP2563350A4 (en) THERAPEUTIC REGIME AND METHOD FOR THE TREATMENT OR IMPROVEMENT OF VIEW DISORDERS ASSOCIATED WITH ENDOGENOUS RETINOID DEFICIENCY
WO2019191279A3 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
MX2015011869A (es) Composiciones, aditivos, y metodos para mitigar o controlar polvo de semilla.
EA201591623A1 (ru) СОЕДИНЕНИЯ, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ПУТЕМ ИНГИБИРОВАНИЯ АКТИВНОСТИ ТРФ-β